ArticleScience advances2021
Sustained and targeted delivery of checkpoint inhibitors by metal-organic frameworks for cancer immunotherapy.
Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 102 citations in OpenAlex.
- Enhancing the targeting ability of metal-organic frameworks in cancer therapy and diagnosis.Nature reviews. Chemistry · 2026Review
- Tumor lysate-cloaked CuMOF-sorafenib nanoassembler: A synergistic cuproptosis-ferroptosis nanoweapon against tumors.Materials today. Bio · 2026Article
- Insights and advances of theranostic nanoscale metal-organic frameworks.Mikrochimica acta · 2025Review
- Metal-organic frameworks as therapeutic chameleons: revolutionizing the cancer therapy employing novel nanoarchitectonics.Asian journal of pharmaceutical sciences · 2025Review
- Tumor microenvironment-activated Zn//MnOScience advances · 2025Article
- Review
- Metal-organic framework-based smart stimuli-responsive drug delivery systems for cancer therapy: advances, challenges, and future perspectives.Journal of nanobiotechnology · 2025Review
- Recent advances in zeolitic imidazolate frameworks as drug delivery systems for cancer therapy.Asian journal of pharmaceutical sciences · 2025Review
- Biomimetic functionalized metal organic frameworks as multifunctional agents: Paving the way for cancer vaccine advances.Materials today. Bio · 2024Review
- Metal-Organic Framework-Mediated Delivery of Nucleic Acid across Intact Plant Cells.ACS applied materials & interfaces · 2024Review
- Review
- Inorganic Nanoparticle Functionalization Strategies in Immunotherapeutic Applications.Biomaterials research · 2024Review
- Drug delivery methods for cancer immunotherapy.Drug delivery and translational research · 2024Review
- Nano-Drug Delivery Systems Targeting CAFs: A Promising Treatment for Pancreatic Cancer.International journal of nanomedicine · 2024Review
- Nanoparticles in Medicine: Current Status in Cancer Treatment.International journal of molecular sciences · 2023Review
- Innovative Metal-Organic Frameworks for Targeted Oral Cancer Therapy: A Review.Materials (Basel, Switzerland) · 2023Review
- Rhodamine B-Conjugated Fluorescent Block Copolymer Micelles for Efficient Chlorambucil Delivery and Intracellular Imaging.ACS omega · 2023Article
- Hybrid Nanomaterials for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Systematic design of cell membrane coating to improve tumor targeting of nanoparticles.Nature communications · 2022Article
- Boosting Protein Encapsulation through Lewis-Acid-Mediated Metal-Organic Framework Mineralization: Toward Effective Intracellular Delivery.Chemistry of materials : a publication of the American Chemical Society · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The major impediments to the implementation of cancer immunotherapies are the sustained immune effect and the targeted delivery of these therapeutics, as they have life-threatening adverse effects. In this work, biomimetic metal-organic frameworks [zeolitic imidazolate frameworks (ZIFs)] are used for the controlled delivery of nivolumab (NV), a monoclonal antibody checkpoint inhibitor that was U.S. Food and Drug Administration-approved back in 2014. The sustained release behavior of NV-ZIF has shown a higher efficacy than the naked NV to activate T cells in hematological malignancies. The system was further modified by coating NV-ZIF with cancer cell membrane to enable tumor-specific targeted delivery while treating solid tumors. We envisage that such a biocompatible and biodegradable immunotherapeutic delivery system may promote the development and the translation of hybrid superstructures into smart and personalized delivery platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.